Weixin Share

Preparation of a Successful CTD with Quality by Design (QbD)

<span style="font-family: arial, helvetica, sans-serif; font-size: 16px;"><span style="font-family: arial, helvetica, sans-serif; font-size: 16px;">Untitled Document</span></span>

[中文]  [English]

Overview

The workshop will share and discuss requirements and experience on how to build up a high quality  CTD dossier with focus on quality  elements, considerations during  the development of a new medicinal product (MP), and practices  for compiling a high quality dossier  for successful global submission  and review for generic products.


Featured Topics
  • CTD, eCTD
  • Drug Legislation and Drug Regulation
  • Residual Solvents – Case Study
  • ICH Q8/Q9/Q10 and Q11 Quality by Design
  • Communication Between Authority and Industry – Case Study
  • Quality Target Product Profile – Interactive Workshop
  • Quality Risk Management – Case Study


Learning Objective
  • Identify the recent requirements for developing drug substance and drug products and setting up a registration dossier
  • Define the requirements for developing a product and discuss how to prepare the ICH Q8/Q9/Q10 and Q11 with Quality by Design
  • Discuss the legal background of the dossier requirements and identify the relevant guidelines
  • Demonstrate optimal presentation of information and justifications for regulatory submissions

 

Who Should Attend
  • Reviewers from Regulatory Agencies
  • Pharmaceutical Industry Professionals
  • Regulatory Affairs, and R&D Professionals
  • Quality Assurance and Manufacturing Professionals

 

Program Committe Co-Chairs

REN Yi, PhD

General Manager, Nanjing Medichem Bio-Pharmaceutical Development Co.

 

Melly LIN

Regulatory Manager Technical Regulatory Policy, Roche (China) Holding Ltd.

  

Key Instructors

Christa Wirthumer-Hoche PhD

Head of Austrian Medicines and Medical Devices Agency (AGES)

Head of Institute for Marketing Authorisation of Medicinal Products and Lifecycle Management


Fritz ERNI PhD

CMC Consultant

Switzerland Member of the ICH Q8 Expert Working Group and ICH Q8/Q9/ Q10 Implementation Working Group Topic

Leader of the European Industry (EFPIA) for Drug Impurities


Program Agenda [Download PDF]
Day 1 | December 8, Monday
7:30-9:00

Registratiion

9:00-9:30

Welcome and Introduction

9:30-10:30

Session 1: China CTD Requirements and Practices  

CFDA Speaker Invited

10:30-11:00

Session 2: Drug Legislation and Drug Regulation

Christa Wirthumer-Hoche PhD

  • Development  of drug legislation
  • Drug regulations in the EU
  • Regulatory  bodies, structure, responsibilities
  • Communication  with and between regulatory agencies
11:00-11:15

Coffee Break

11:15-12:15

Session 3: Introduction to the Common Technical Document Structure of the licensing dossier

Christa Wirthumer-Hoche PhD

  • Structure of the CTD (Module 1 – 5)
    • Relevant guidance  documents
    • Focus on Module 3 - Quality
  • eCTD
    • current guidance documents
    • readiness to prepare (by industry) and accept eCTD (by authority)
    • future of the eCTD
12:15-13:30
Lunch
13:30-14:15

Session 4: Quality of Active Substance - necessary documentation

Christa Wirthumer-Hoche PhD

  • Active Substance
    • Active Substance Master File
    • Certificate of Suitability
  • Impact of the EU-Directive on Falsified Medicines
14:15-15:15

Session 5: Impurity testing : Experience and new trends of ICH Q3A/B/C

Fritz Erni PhD

  • Impurities in drug substance
  • Degradation products in drug products
  • Residual solvents
15:15-15:30

Coffee Break

15:30-17:30

Session 6: Case Study Residual Solvents

All Participants

         

Day 2 | Tuesday, December 9
8:30-10:00

Session 7: Specific Requirements for Different Types of Applications

Christa Wirthumer-Hoche PhD

  • Information for bibliographical applications
    • Legal provisions concerning well established use applications
  • Information for generic, “hybrid” or bio-similar applications
    • Legal provisions concerning generics
    • Data protection period
  • Information for Informed Consent Applications
10:00-10:15

Coffee Break

10:15-12:00

Session 8: Quality Risk Management

Fritz Erni  PhD and Christa Wirthumer-Hoche PhD

  • Introduction to the Quality Risk Management and to the case study
  • Start working in groups
  • Discussion of the case study
  • Risk based review
12:00-13:30
Lunch Break
13:30-14:30

Session 9

Fritz Erni PhD

  • Stability testing
    • Discussion of the relevant guidelines
    • Practical examples
  • Setting of Specifications
14:30-14:45

Coffee Break

14:45-17:00

Session 10: Case Study

All Participants

 

Day 3 | Wednesday, December 10
8:30-10:00

Session 11: Pharmaceutical Development (3.2.P.2)

Fritz Erni  PhD

  • Discussion of important chapters
  • ICH Q8/Q9/Q10 and Q11 Quality by Design
    • What is Quality by Design
    • What are the optional possibilities and opportunities
    • ICH Q8 – drug product, ICH Q 11  - drug substance
    • Quality Risk Management (Q9) and how to implement Quality
    • Risk management in a dossier
10:00-10:15

Coffee Break

10:15-12:00

Session 12: The EU Regulatory Process

Christa Wirthumer-Hoche PhD

  • Centralized / Decentralized / Mutual Recognition Procedure
  • QbD – views of the regulators
  • Cooperation between assessors and inspectors
12:00-13:30
Lunch Break
13:30-14:30

Session 13: Case Study

Fritz Erni  PhD and Christa Wirthumer-Hoche PhD

  • Planning and organising a Meeting with authority
    • Scientific Advice, Pre-submission meeting, oral hearing during a procedure
                         
14:30-15:00

Coffee Break

15:00-16:00

Session 14: Maintenance of Marketing Authorisations

Fritz Erni  PhD and Christa Wirthumer-Hoche PhD

  • Variations / Post approval changes
  • Legal framework
    • Definition of Variations
    • Classification of a variation
    • Procedural Guidance               
  • New provision for variations, to enhance regulatory flexibity
    • Post Approval Management Protocol
  • The Classification Guideline
16:00-16:30

Final Discussion & Closing Remarks

Registration

Type Sales End Price

Industry-Member

2014-12-10 16:30 ¥3500

Industry-NonMember

2014-12-10 16:30 ¥4300

Government-Member

2014-12-10 16:30 ¥2600

Government-NonMember

2014-12-10 16:30 ¥3400

Academia/ Nonprofit-Member

2014-12-10 16:30 ¥2600

Academia/ Nonprofit-NonMember

2014-12-10 16:30 ¥3400
Amount: ¥ 0

Date Time

2014-12-08 09:00 - Start

2014-12-10 16:30 - End

96 23 11
Address
  • 中国 上海 杨浦区
  • Shanghai, China

Contact Us

Your Name: *
Your Email: *
Cell phone:
Subject: *
Message: *